CardiologyNOW | Begin CME/CE | Pri-Med

Join your clinician colleagues and expert faculty for CardiologyNOW: A Pri-Med Virtual Conference on Thursday, September 30. Headlined by expert cardiologist Peter Libby, MD, from Harvard Medical School and Brigham and Women's Hospital, this free half day of learning will provide you with the latest clinical insights in cardiovascular medicine and keep you informed on the most current clinical strategies relevant to your daily practice.
Earn up to 3.00 AMA PRA Category 1 Credits™ and 3.00 ABIM Medical Knowledge MOC Points, or 3.00 AANP contact hours of continuing education, including 1.66 hours of pharmacology. Your free registration includes the full conference, but you're welcome to join the sessions that best fit your schedule. Agenda and details are subject to change.
To register for this virtual conference, you will be asked to sign in to your Pri-Med account. If you do not have an account, you can create your free account now, which takes less than two minutes.

Agenda

  CME/CE Accredited Session

Non-CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

8–9am ET    CME/CE Accredited Session

Cardiology

 

With the COVID-19 pandemic moving through the country, it is important for clinicians to have the most up-to-date information. Join this session with Dr. Peter Libby to learn about the cardiovascular complications of COVID-19 and how you can help patients facing these issues. 

Peter Libby, MD

Cardiovascular Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA

9:10–10:10am ET    CME/CE Accredited Session

Cardiovascular Medicine

Beating the Odds: New Advances in Overcoming the Challenges of HFrEF  

Ty J. Gluckman, MD, FACC, FAHA | Alison L. Bailey, MD, FACC, FAACVPR

 

If you treat patients with heart failure, you know the substantial burden of morbidity, mortality, reduced quality of life, and financial expenditure they face. With disease prevalence on the rise, you are likely to see even more cases in your practice. This educational activity arms you with the knowledge you need to offer this patient population the best possible care. Expect to learn about updated guidelines for heart failure with reduced ejection fraction (HFrEF), the key role of cardiac biomarkers in diagnosing and managing this disease, emerging treatment options, and exciting new clinical trial results.

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR

Default Biography Avatar

Alison L. Bailey, MD, FACC, FAACVPR

Chief, Cardiology, Centennial Heart at Parkridge, Co-director of the Center for Heart, Lung and Vascular Health at Parkridge, Parkridge Health System, Medical Director, Cardiovascular Disease, Chattanooga, TN

Supported by Merck Sharp & Dohme Corp.

10:20–11:05am ET    Non-CME Industry Theater

Cardiology

The Continuum of Heart Failure 

Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA

 

The objective of this program is to discuss the pathophysiology, disease burden, and management of heart failure (HF). The program will present data on HF prevalence and health outcomes, review the implications of type 2 diabetes as a common comorbidity, and provide guidance on diagnosing HF. It will conclude with a brief overview of current treatment options for HF.

Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA

Medical Director, CHF, Abrazo Arizona, Heart Hospital and Abrazo Health, Network, Clinical Professor of Medicine, University, of Arizona, Founding Member and Past President,, Cardiorenal Society of America (CRSA)

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

11:15am–12:15pm ET    CME/CE Accredited Session

Cardiology

Taking Diabetes to Heart: Using Antihyperglycemic Agents to Reduce Cardiovascular Risk 

Christopher Cannon, MD | Tina K. Thethi, MD, MPH, FACE

 

In recent years there has a been paradigm shift in how to individualize use of antihyperglycemic agents in people with type 2 diabetes, with cardiac history and risk factors significantly affecting the guideline-recommended agents. In addition metformin, SGLT2 inhibitors and GLP-1 receptor agonists have become an integral part of treatment of patients with diabetes and comorbid cardiac and renal disease. Join expert faculty in this data driven session as they review the and discuss strategies to improve use of these agents in management of type 2 diabetes.

Christopher Cannon, MD

Cardiovascular Division, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA

Tina K. Thethi, MD, MPH, FACE

Associate Professor, Tulane University School of Medicine, New Orleans, LA

Supported by Novo Nordisk Inc.

12:25–12:35pm ET    Non-CME Industry Theater

 

A brief review on how hospitalizations impact heart failure trajectory and how guideline-directed care can improve outcomes for patients with heart failure. Dr. Jennifer Brown presents compelling information on why hemodynamic status and biomarkers (such as BNP and NT-proBNP) are important prognostic indicators in patients hospitalized due to heart failure. 

For more HF and cardiovascular disease education content, please see www.HallsofScience.com  

Sponsored by Novartis Pharmaceuticals Corporation

12:40–12:50pm ET    Non-CME Industry Theater

 

A brief review on how hospitalizations impact heart failure trajectory and how guideline-directed care can improve outcomes for patients with heart failure. Dr. Jennifer Brown presents compelling information on why hemodynamic status and biomarkers (such as BNP and NT-proBNP) are important prognostic indicators in patients hospitalized due to heart failure. 

For more HF and cardiovascular disease education content, please see www.HallsofScience.com  

Sponsored by Novartis Pharmaceuticals Corporation